POTELIGEO 4 mg/mL
mogamulizumab-kpkc · INJECTION · Kyowa Kirin, Inc.
No Recall History
Plain English
POTELIGEO is a injection containing mogamulizumab-kpkc at 4 mg/mL, taken intravenous. Manufactured by Kyowa Kirin, Inc..
Key Facts
- Brand Name
- POTELIGEO
- Generic Name
- mogamulizumab-kpkc
- NDC Code (Product)
42747-761- Manufacturer
- Kyowa Kirin, Inc.
- Strength
- 4 mg/mL
- Dosage Form
- INJECTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA761051
- Drug Class
- Chemokine Receptor Type 4 Interaction [EPC]; Monoclonal Antibody [EPC]
- Marketing Start
- 08/08/2018
Recall History
No Recall HistoryFrequently Asked Questions
What is POTELIGEO used for?
POTELIGEO contains mogamulizumab-kpkc. It is a injection taken intravenous. Consult your doctor for specific uses.
Is POTELIGEO a controlled substance?
POTELIGEO is not classified as a controlled substance by the DEA.
What is the generic name for POTELIGEO?
The generic name for POTELIGEO is mogamulizumab-kpkc. There are no other listed brand versions of mogamulizumab-kpkc.
What is the NDC code for POTELIGEO 4 mg/mL?
The NDC (National Drug Code) for POTELIGEO 4 mg/mL is 42747-761, listed by Kyowa Kirin, Inc..
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)